Earlier, Aestus has identified several products to treat certain psychiatric disorders. Now in partnership with Eisai, Aestus is expected to use those products for potential subsequent development in clinical trials.
Tage Honore, co-founder and CEO of Aestus, said: “Aestus is delighted that this collaboration with Eisai combines our strengths in this work to develop novel therapies for people affected by psychiatric disorders.
“Eisai’s proven talent and expertise will enable us to move drug candidates through the clinical development process efficiently with the goal of bringing innovative new treatments to the market place.
“It is our hope that the products we discover through this collaboration will improve the quality of life for the millions of sufferers of psychiatric disorders and their families.”